Xu W - Search Results

1

Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.

Wei Y, Wu S, Xu W, Liang Y, Li Y, Zhao W, Wu J. Wei Y, et al. Among authors: xu w. Thorac Cancer. 2017 Jan;8(1):26-32. doi: 10.1111/1759-7714.12400. Epub 2016 Nov 4. Thorac Cancer. 2017. PMID: 27813328 Free PMC article.

2

Combined effects of klotho and soluble CD40 ligand on A549 lung cancer cells.

Wang X, Chen B, Xu W, Liu S, Zhao W, Wu J. Wang X, et al. Among authors: xu w. Oncol Rep. 2011 May;25(5):1465-72. doi: 10.3892/or.2011.1178. Epub 2011 Feb 9. Oncol Rep. 2011. PMID: 21308354

3

Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway.

Wang Y, Chen L, Huang G, He D, He J, Xu W, Zou C, Zong F, Li Y, Chen B, Wu S, Zhao W, Wu J. Wang Y, et al. Among authors: xu w. PLoS One. 2013;8(2):e57391. doi: 10.1371/journal.pone.0057391. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437382 Free PMC article.

4

Self-complementary adeno-associated virus 5-mediated gene transduction of a novel CD40L mutant confers direct antitumor effects in lung carcinoma.

Xu W, Xu Y, Wei Y, Tan Y, Zhao H, Zhao W, Wu J. Xu W, et al. Among authors: xu y. Mol Med Rep. 2015 Jan;11(1):482-8. doi: 10.3892/mmr.2014.2765. Epub 2014 Oct 24. Mol Med Rep. 2015. PMID: 25352298

5

Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells.

Chen B, Tan Y, Liang Y, Li Y, Chen L, Wu S, Xu W, Wang Y, Zhao W, Wu J. Chen B, et al. Among authors: xu w. Oncol Lett. 2017 Jan;13(1):423-428. doi: 10.3892/ol.2016.5430. Epub 2016 Nov 24. Oncol Lett. 2017. PMID: 28123577 Free PMC article.

6

The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects.

Chen B, Qiu LX, Li Y, Xu W, Wang XL, Zhao WH, Wu JQ. Chen B, et al. Among authors: xu w. Lung Cancer. 2010 Dec;70(3):247-52. doi: 10.1016/j.lungcan.2010.03.011. Epub 2010 Apr 14. Lung Cancer. 2010. PMID: 20395011

7

Anti-tumor activity of gene transfer of the membrane-stable CD40L mutant into lung cancer cells.

Xu W, Li Y, Wang X, Wang C, Zhao W, Wu J. Xu W, et al. Int J Oncol. 2010 Oct;37(4):935-41. doi: 10.3892/ijo_00000744. Int J Oncol. 2010. PMID: 20811715

8

Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells.

Wu SS, Xu W, Liu S, Chen B, Wang XL, Wang Y, Liu SF, Wu JQ. Wu SS, et al. Among authors: xu w. Acta Pharmacol Sin. 2011 Mar;32(3):393-8. doi: 10.1038/aps.2010.216. Epub 2011 Jan 31. Acta Pharmacol Sin. 2011. PMID: 21278781 Free PMC article.

9

[The expression and significance of stem cell transcription factor Sox2 in lung carcinoma].

Xu W, Wei Y, Tan Y, Xu W, Cheng SY, Wu J. Xu W, et al. Zhongguo Fei Ai Za Zhi. 2013 Nov;16(11):591-5. doi: 10.3779/j.issn.1009-3419.2013.11.05. Zhongguo Fei Ai Za Zhi. 2013. PMID: 24229625 Free PMC article. Chinese.

10

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib.

Xu W, Wei Y, Wu S, Wang Y, Wang Z, Sun Y, Cheng SY, Wu J. Xu W, et al. Cell Biosci. 2015 Feb 5;5:7. doi: 10.1186/2045-3701-5-7. eCollection 2015. Cell Biosci. 2015. PMID: 25973173 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,462 results

Search Page

Filters